Skip to content

Financial Post profiles OtoSim Inc.’s innovative medical learning device

OtoSim Inc. Logo“If there’s one profession for which you don’t want students to have learning gaps, it’s medicine,” Rebecca Walberg wrote in the Smart Shift: Agenda for Innovation section in the Financial Post on May 7 (reprinted in the Vancouver Sun on May 9 and in the Calgary Herald on June 6, 2013). “Yet that’s exactly what Dr. Paolo Campisi saw while working with medical students at the University of Toronto.”

Walberg’s article, “Innovation in medical learning a Canadian business success story,” describes the process Campisi and his colleague and co-founder Dr. Vito Forte, both of the Hospital for Sick Children and cross-appointed to U of T, undertook to design the OtoSim device, which addresses the gap in how students were learning skills associated with otolaryngology (ear, nose and throat diseases or infections).

Here’s an excerpt (beginning with a quote from Dr. Forte):

“The answer wasn’t more time to lecture or show big pictures on a screen, but rather some kind of instrument that would mimic the experience of looking into an ear with an otoscope. And we went through a number of prototypes developing a simulator that can do just that.”

The result is the OtoSim, brought to market and sold by OtoSim Inc. The simulator consists of a rubber ear made to scale, and a computer display integrated into the model where the eardrum would be in a patient, which can display images of ear canals that correspond to a wide range of medical conditions.

Continue Reading

TechWomen Canada selects UTEST co-director for Silicon Valley program

Lyssa Neel
Lyssa Neel, co-director of UTEST and MaRS Innovation project manager

MaRS Innovation’s (MI) Lyssa Neel, co-director of the UTEST program and project manager, has been selected to represent MI’s ICT start-up companies at the TechWomen Canada program in San Francisco, which runs May 13 to 16, 2013.

The announcement was covered in TechVibes:

TechWomen Canada is run by the Canadian Consulate and is focused on providing Canadian women leaders in the ICT sector an opportunity to expand both professional and business networks in Silicon Valley.

Continue Reading

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Downtown Chicago skyline in late April
Chicago‘s famous downtown skyline during the 2013 BIO Convention.

Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.

The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, along with sector-based organizations and associations, to Chicago.

According to a press release issued by the conference organizers, BIO 2013 offered “a record number of partnering meetings and panel sessions on the latest science, policy issues and business opportunities and challenges facing the biotechnology industry.”

Continue Reading

Flybits recognized as a context-aware tool for marketing professionals

The Flybits mobile user interface presents relevant information from surrounding geo-fences (zones).
The Flybits mobile user interface presents relevant information from surrounding geo-fences (zones).

TORONTO, Canada (April 24, 2013) — Flybits Inc. announced today that  Forrester Research Inc. has recognized Flybits, a Toronto-based start-up company, as a tool for on-demand marketing processes in a recent report.

The February 2013 Forrester report, written by Anthony Mullen, “Emerging Touchpoints Require a Marketing Mind Shift,” states that to master the new basics, marketing professionals must increase corporate spending on innovation and formalize working relationships in areas such as customer experience, analytics, IT and product design — all of which the Flybits framework addresses.

To address the problem of information overload on mobile devices, Flybits unifies the mobile user experience across multiple channels, creating a cohesive mobile presence for a company’s communication needs. Rather than introducing heterogeneous mobile channels to users, all relevant information can be structured within Flybits Zones — semantic-driven, rule-oriented geo-fences.

Continue Reading

ClevrU Corp. acquires NewMindsets Inc. to transform online education market

Deal strengthens competitiveness of online learning platform for global mobile learners

The ClevrU platform will integrate New Mindsets Inc.'s technology through this acquisition.
The ClevrU platform (shown here) will integrate NewMindsets Inc.’s technology through this acquisition.

WATERLOO, ON, Canada (April 23, 2013) — ClevrU Corporation today announced that it has acquired NewMindsets Inc., a company founded on online pedagogy researched and developed by two Schulich School of Business professors that has provided leading-edge educational content and services to over 10,000 Schulich students at York University over the past decade.

Through the acquisition, ClevrU will fully integrate NewMindsets’ proven e-teaching pedagogy in leadership, researched and developed by Professors Gareth Morgan and Jean Adams, into its world-class e-teaching platform, to be presented to York as a pilot and then delivered to millions of students worldwide.

TechVibes, EdSurge, Private Equity Hub, Yonge Street Media, and the Waterloo Record covered this announcement. The release is also viewable on CNW and in Chinese (.pdf).

The two companies announced a partnership in October 2012 to establish a second-generation online learning standard.

Continue Reading

MaRS Innovation announces new strategic partnership with Pfizer

MaRS Innovation LogoTORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.

Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.

“There’s growing consensus that transferring technologies from the university lab bench and into the market requires unique public-private partnerships,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Partnering with MaRS Innovation gives Pfizer access to Toronto’s robust innovation pipeline and a close look at emerging IP from Canada. It signals both the strength and attractiveness of our commercialization model and Toronto-based research technologies to global industry players.”

“Our government is committed to making Ontario the best place to translate great ideas into innovative products that will gain demand around the world,” said the Honourable Reza Moridi, Ontario Minister of Research and Innovation. “Today’s announcement from MaRS Innovation is an exciting collaboration with Pfizer that will both advance healthcare technologies for Ontarians and help to strengthen our economy.”

Continue Reading

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada

CHICAGO, Illinois April 22, 2013Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.

Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.

This partnership announcement was covered by PEHub.

IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Continue Reading

Minuum’s crowdfunding campaign raises 873 per cent of initial goal

Over 9,600 people funded Toronto start-up’s one-dimensional mobile keyboard

Final tally for Minuum's Indiegogo campaign
The final tally for Minuum’s Indiegogo campaign: $87,369 in one month from 9,648 supporters.

TORONTO, Canada (April 18, 2013) — The Indiegogo campaign for Minuum, “the little keyboard for big fingers,” created by Whirlscape Inc., has closed after raising $87,369 in one month.

Minuum is a one-dimensional, tiny keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm allows highly imprecise typing, configuring the difference between what you type and what you mean in real time and getting it right even if you miss every single letter.

Read about the Minuum launch and reaching its $60,000 stretch milestone in previous posts. The posts include links to Minuum’s international media coverage. Most recently, their technology and Indiegogo success were featured in The Verge, the Financial Post, Mobile Syrup (includes an excellent Youtube interview with founder Will Walmsley, embedded below) and Tech2.

The campaign’s initial goal — $10,000 to fund the launch of an Android keyboard app — was reached within 14 hours. Since its launch on March 18, the campaign video has been viewed over 1.1 million times.

Did you know Minuum’s campaign is in Indiegogo’s top 10 of all time for projects with the largest number of supporters?

Continue Reading

Stem Cell Therapeutics licenses UHN’s Clinical Cancer Stem Cell Program

Stem Cell Therapeutics Corp. logo
Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.

The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.

This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.

The initial consideration of $1.6 million for the UHN License is to be satisfied by the issuance of 5,028,571 SCT common shares and 1,600,000 SCT common share purchase warrants to UHN and MaRS Innovation, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.

Continue Reading
Back To Top